SUFENTANIL CITRATE INJECTION USP SOLUTION

Страна: Канада

мова: англійська

Джерело: Health Canada

Активний інгредієнт:

SUFENTANIL (SUFENTANIL CITRATE)

Доступна з:

STERIMAX INC

Код атс:

N01AH03

ІПН (Міжнародна Ім'я):

SUFENTANIL

Дозування:

50MCG

Фармацевтична форма:

SOLUTION

Склад:

SUFENTANIL (SUFENTANIL CITRATE) 50MCG

Адміністрація маршрут:

INTRAVENOUS

Одиниць в упаковці:

10X1ML/5X5ML

Тип рецепту:

Narcotic (CDSA I)

Терапевтична области:

OPIATE AGONISTS

Огляд продуктів:

Active ingredient group (AIG) number: 0144821002; AHFS:

Статус Авторизація:

APPROVED

Дата Авторизація:

2015-08-12

Характеристики продукта

PRODUCT MONOGRAPH
INCLUDING PATIENT MEDICATION INFORMATION
N
SUFENTANIL CITRATE INJECTION USP
Sufentanil Citrate Injection
50 mcg/mL
USP
Opioid Analgesic
SteriMax Inc.
2770 Portland Drive
Oakville ON
L6H 6R4
Date of Revision: May 22, 2019
Submission Control No: 226452
_Sufentanil Citrate Injection USP _
_Page 2 of 42_
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
.........................................................3
SUMMARY PRODUCT INFORMATION
........................................................................3
INDICATIONS AND CLINICAL USE
..............................................................................3
CONTRAINDICATIONS
...................................................................................................4
WARNINGS AND PRECAUTIONS
..................................................................................5
ADVERSE REACTIONS
..................................................................................................13
DRUG INTERACTIONS
..................................................................................................15
DOSAGE AND ADMINISTRATION
..............................................................................17
OVERDOSAGE
................................................................................................................20
ACTION AND CLINICAL PHARMACOLOGY
............................................................21
STORAGE AND STABILITY
..........................................................................................24
SPECIAL HANDLING INSTRUCTIONS
.......................................................................24
DOSAGE FORMS, COMPOSITION AND PACKAGING
.............................................24
PART II: SCIENTIFIC INFORMATION
.............................................................................275
PHARMACEUTICAL INFORMATION
........................................................................275
DETAILED PHARMACOLOGY
............................................................